Perrett, Madeleine
Gohil, Nisha
Tica, Otilia
Bunting, Karina V.
Kotecha, Dipak http://orcid.org/0000-0002-2570-9812
Funding for this research was provided by:
Amomed (independent systematic review)
British Heart Foundation (Career Development Research Fellowship (FS/CDRF/21/21032), Accelerator to the University of Birmingham (AA/18/2/34218))
Medical Research Council (MRC Health Data Research UK (HDRUK/CFC/01))
Horizon 2020 Framework Programme (EU/EEPIA Innovative Medicines Initiative (BigData@Heart 116074))
National Institute for Health and Care Research (Birmingham Biomedical Research Centre (NIHR203326))
UK National Health Service -Data for R&D- (Subnational Secure Data Environment programme West Midlands)
Article History
Received: 21 April 2023
Accepted: 22 August 2023
First Online: 1 September 2023
Declarations
:
: MP and NG have nothing to disclose. OT is funded through grants from the EU/EEPIA Innovative Medicines Initiative (BigData@Heart 116074) and Amomed Pharma. KB was the Research fellow for the RATE-AF trial funded by the NIHR (NIHR CDF-2015-08-074) and has been awarded a grant from the University of Birmingham’s British Heart Foundation Accelerator Award (BHF AA/18/2/34218). DK reports grants from the National Institute for Health Research (NIHR CDF-2015-08-074 RATE-AF; NIHR130280 DaRe2THINK; NIHR132974 D2T-NeuroVascular; NIHR203326 Biomedical Research Centre), the British Heart Foundation (PG/17/55/33087, AA/18/2/34218 and FS/CDRF/21/21032), the EU/EFPIA Innovative Medicines Initiative (BigData@Heart 116074), EU Horizon/UKRI (HYPERMARKER 101095480), UK National Health Service -Data for R&D- Subnational Secure Data Environment programme, UK Dept. for Business, Energy & Industrial Strategy Regulators Pioneer Fund, the Cook & Wolstenholme Charitable Trust, and the European Society of Cardiology supported by educational grants from Boehringer Ingelheim/BMS-Pfizer Alliance/Bayer/Daiichi Sankyo/Boston Scientific, the NIHR/University of Oxford Biomedical Research Centre and British Heart Foundation/University of Birmingham Accelerator Award (STEEER-AF). In addition, he has received advisory board fees from Bayer, Amomed and Protherics Medicines Development, all outside the submitted work, and his institution has received research grants from these organisations.